Ftse Mib
33.629,21
-0,32%
DAX
18.001,60
0,54%
S&P 500
5.127,79
1,26%
NASDAQ
16.156,33
1,99%
Bitcoin
63.620,19
-0,43%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Lixte Biotechnology Holdings Inc (LIXT) Lixte Biotechnology Holdings Inc (LIXT) Notizie

Lixte Biotechnology Holdings Inc

LIXT
2,82
-0,0621 (-2,15%)
04 Mag 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
24/4/202421:25APSMixed Shelf Filing Gives Micro Cap Delayed Boost
27/3/202420:35APSBiotech Steals The Show Following Pre-Clinical Data..
27/3/202413:30GLOBENEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE’S LEAD..
21/3/202413:30GLOBELIXTE Provides Update on Progress with LB-100 as a PP2A..
27/2/202422:59EDGAR2Form 8-K - Current report
27/2/202414:30GLOBEProfessor René Bernards to Present New Pre-Clinical Data on..
26/2/202416:48EDGAR2Form 8-K - Current report
26/2/202414:30GLOBELIXTE Biotechnology Enters into Exclusive Immune Oncology..
29/1/202414:30GLOBEFirst Patient Dosed with LIXTE’s LB-100 and GSK’s..
28/11/202323:21EDGAR2Form 8-K - Current report
13/11/202320:28EDGAR2Form 8-K - Current report
13/11/202314:30GLOBELIXTE Biotechnology Provides Update on Clinical Progress and..
09/11/202323:16EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
17/10/202323:27EDGAR2Form 8-K - Current report
16/10/202320:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/10/202314:30GLOBELIXTE, Netherlands Cancer Institute, and Oncode Institute to..
10/10/202321:55EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
10/10/202321:47EDGAR2Form DEF 14A - Other definitive proxy statements
09/10/202314:30GLOBELIXTE Biotechnology Holdings Announces the Passing of its..
06/10/202302:39EDGAR2Form 4/A - Statement of changes in beneficial ownership of..
06/10/202302:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/10/202300:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/9/202322:05EDGAR2Form PRE 14A - Other preliminary proxy statements
27/9/202312:15EDGAR2Form 8-K - Current report
27/9/202312:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/9/202314:30GLOBELIXTE Appoints Bas van der Baan as President and Chief..
20/9/202317:20EDGAR2Form 8-K - Current report
20/9/202314:30GLOBELIXTE Biotechnology Announces a Supported Collaborative..
11/8/202322:20EDGAR2Form S-3 - Registration statement under Securities Act of..
09/8/202314:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
21/7/202322:05EDGAR2Form 8-K - Current report
20/7/202322:25EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
20/7/202322:05GLOBELIXTE Biotechnology Announces Closing of $3.5 Million..
20/7/202317:45EDGAR2Form 8-K - Current report
18/7/202314:00GLOBELIXTE Biotechnology Announces Pricing of $3.5 Million..
17/7/202314:30GLOBEPreclinical Results of LIXTE Biotechnology’s Collaboration..
07/7/202320:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/7/202316:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/7/202316:57EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/7/202316:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/6/202314:30GLOBELIXTE Biotechnology Holdings, Inc. Regains Compliance with..
07/6/202314:30GLOBELIXTE Biotechnology and the Spanish Sarcoma Group Enroll..
02/6/202318:30GLOBELIXTE Biotechnology Holdings, Inc. Announces 1-for-10..
30/5/202314:30GLOBERecently Published Independent Research Reveals New..
Apertura: 3,00 Min: 2,8735 Max: 3,002
Chiusura: 2,8821

La tua Cronologia

NASDAQ
LIXT
Lixte Biotechnology
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network